Background: The role of estrogen in the growth and survival of ovarian cancer cells is controversial. In this study, we investigated the changes in cell-cycle regulatory proteins in ovarian cancer cell lines after estrogen treatment to explore the role of estrogen in ovarian cancers. Methods: Two ovarian adenocarcinoma cell lines were used for the study: the first, OC-117-VGH, was deficient in estrogen receptors (ER)a and ERb, and the second, OVCAR3, was positive for ERa and ERb. Serial concentrations of estrogen were used to evaluate the effects of estrogen on the survival of ovarian cancer cells. The cell-cycle regulatory proteins, including cyclin D1, cyclin E, p16/INK4a, and p27/KIP1, were used to check the possible mechanism of an estrogen effect on survival of the cancer cell line. Results: Estrogen 0.01e1.0 mM inhibited the growth of both cell lines. There were no differences in cyclin D1 and E expression between the two cell lines after estrogen treatment, but the expression of p16/INK4a and p27/KIP1 was significantly higher in the OC-1170-VGH cell line than in the OVCAR3 cell line. Conclusion: Although the ER-positive and ER-negative ovarian cancer cell lines were inhibited by estrogen, the influence of cell-cycle regulatory proteins was different between the two, suggesting that the inhibitory effect of estrogen on ovarian cancer cell lines might be mediated through different pathways.
Introduction
Ovarian cancer is the leading cause of cancer mortality in female patients in Taiwan. 1, 2 The standard treatment for ovarian cancer is an extensive surgical resection of the primary tumor and all visible tumors in the abdominal cavity, followed by postoperative adjuvant carboplatin and paclitaxel chemotherapy. A resistance to chemotherapy usually suggests a poor prognosis.
6e8 Therefore, any agent other than platinums and the taxanes regimen that might increase the response or survival of women with ovarian cancer would be well received.
9e12 For example, recent epidemiologic studies have suggested that estrogen might promote ovarian tumor progression in postmenopausal women. 13 This is supported by the Women's Health Initiative (WHI) randomized trial. 14, 15 There is a growing body of experimental evidence that estrogen may play important roles in ovarian carcinogenesis, including the control of cellular differentiation and growth, and in the apoptosis of ovarian cancer cells. 16 However, the exact nature of these roles remains the subject of controversy. 16, 17 In general, ovarian cancer is rarely responsive to hormone therapy. 18 Although the cause of this lack of responsiveness is still uncertain, the loss of estrogen receptor (ER) might be one reason. 19, 20 Estrogen signaling is mediated by receptor binding in the nucleus, including fos, myc, and cyclin D. 21 Cyclins, including cyclin D1, 22e25 cyclin E, 23, 25 p16/INK4a, 26 and p27/KIP1, 27 are cell-cycle regulatory proteins that are important factors in cell cycles, and are the essential protein for the cell differentiation process. 22 The relationship between cell-cycle regulatory proteins and the ER-mediated effect has been reported. 27 For example, p16/INK4a, and p27/KIP1 were reported to influence the cancer behavior-invasiveness of endometrial cells through ER, 27 suggesting the possibility that these cell-cycle regulatory proteins could be involved in gynecologic cancer cells, especially hormone-related gynecologic cancers, which may be mediated through an ER pathway; therefore, the question can be raised as to whether estrogen or other hormones could be used in the management of various kinds of gynecologic cancers.
In the current study, we used an established ovarian adenocarcinoma cell line, OC-117-VGH, which is negative for ERa and ERb, and OVCAR3, which is positive for ERa and ERb to investigate the effect of estrogen on ovarian cancer cell lines, including their growth and the related cell-cycle regulatory proteins.
Methods

Cell line and culture
An ovarian adenocarcinoma cell line, OC-117-VGH, was initiated from a clear-cell adenocarcinoma that had been removed from a 56-year-old woman who underwent debulking surgery for surgicopathologic stage IIIC ovarian cancer in 1997. 16 Human ovarian cancer cells (OVCAR3; American Type Culture Collection, Manassas, VA, USA) were also used in this study. Both cells were grown in culture medium containing a 1:1 mixture of F-12/DMEM (GIBCO BRL, Grand Island, NY, USA), supplemented with 10% fetal calf serum (FBS, HyClone, Logan, UT, USA), 100 U/mL penicillin, 100 mg/mL streptomycin, and 2.5 mg/mL amphotericin B. The cells were incubated at 37 C with 5% carbon dioxide with greater than 95% humidity. The cell culture media were changed twice a week and the cells were subcultured weekly by detachment with 2.5 mg/mL trypsin/0.02% ethylenediaminetetraacetic acid (EDTA) in Dulbecco's phosphatebuffered saline (D-PBS) solution (Gibco BRL, Grand Island, NY, USA). Cells were maintained and subcultured weekly and split at a 1:2 to 1:4 ratio in preparation for subsequent studies.
Expression of ERa and ERb by reverse transcription polymerase chain reaction
We used the TRIzol kit (Tel-Test Inc., Friendswood, TX, USA) to purify the RNA of the ovarian cancer cells. We added 1 mL of TRIzol solution to the drug-treated ovarian cancer cells after centrifugation at 12,500 rpm and 4 C for 30 minutes, collected the upper layer and added isopropanol after another centrifugation at 12,500 rpm and 4 C for 30 minutes, and then washed the RNA twice with 70% alcohol.
We used SuperScript First-Strand Syn (Gibco) reversetranscript RNA to complementary DNA (cDNA), following the manufacturer's protocol, by incubating 1 mg of total RNA with oligo-d(T)12-18 (Invitrogen, Carlsbad, CA, USA) as the initiation primer in a final reaction volume of 20 mL, which has been described elsewhere.
28e30
The primers used for detecting genes by the polymerase chain reaction (PCR) method are as follows. The ERa was amplified using the forward primer 5 0 -TGCCAAGGAGAC TCGCTA-3 0 and reverse primer 5 0 -TCAACATTCTCCCTCC TC-3 0 (11) (amplicon length, 263 base pairs [bp]). The ERb was amplified using the forward primer 5 0 -GTCCATCGC CAGTTATCACATC-3 0 and reverse primer 5 0 -GCCTTACA TCCTTCACACGA-3 0 (amplicon length, 242 bp). 16 The PCR buffer contained 1Â mRNA selective PCR buffer, 5 mM MgCl 2 , 1 mM deoxyribonucleoside triphosphate (dNTP)/ analog mixture, 2.5 U/mL avian myeloblastosis virus (AMV)-optimized Taq polymerase, and 0.4 mM sense-and antisensespecific primers. A total of 5 mL cDNA from each cell and sterile distilled water was added to adjust the final concentration to 50 mL. All transcripts were analyzed in a DNA thermal cycler (PerkineElmer, Norwalk, CT, USA) with the following cycle: a denaturation step of 85 C for 1 minute, an annealing step of 50 C for 1 minute, and an extension step of 72 C for 1 minute, repeated for 30 cycles, then a final primer extension step of 72 C for 5 minutes. PCR products were analyzed by electrophoresis through a 2% agarose gel and visualized by Sybr green II (Amersham Pharmacia USA) staining under ultraviolet illumination. 31 
Estrogen treatment
Aliquots (100 mL) containing 1 Â 10 6 cells/mL were dispensed into a 96-well plate (Corning Inc, Big Flats, NY, USA). Triplicate cultures for each test were incubated for 24 hours at 37 C, and then 100 mL of different concentrations of estrogen were added. 16 Estrogen was added separately to the final concentrations, ranging from 0.01 to 1.0 mM, prepared in a serumfree medium. A serum-free culture medium was used for the control. Cells were treated with estrogen 0.01e1.0 mM for 24, 48, and 72 hours at 37 C, with 5% CO 2 and more than 95% humidity.
Cell survival assay
Cell proliferation assays were automated by adopting a colorbased cell proliferation detection assay and a 96-well plate culture system. The number of viable cells present was assessed with the CellTiter 96 Aqueous (CTAQ) nonradioactive cell proliferation assay system (Promega, Madison, WI, USA). 16 This colorimetric assay determines the number of viable cells on the basis of the conversion of the tetrazolium compound [3-
-tetrazolium] into a formazan that is soluble in tissue culture media. At the last 4-hour segment of estrogen treatment, we added 20 mL per well of CTAQ. At the end, we read the plate with a multiscan (Multiscan, Labsystems, Helsinki, Finland) at an optical density of 490 nm.
Results were expressed as a percentage of cell survival after estrogen treatment in culture media, and compared with the controls. The estrogen-treated survival rates at each concentration were calculated as follows:
Protein concentrations were measured by the Lowry method.
32,33
Enzyme-linked immunosorbent assay detection
To further dissect the role of cell-cycle regulatory proteins in the ovarian cancer cell lines when estrogen was used with these ovarian cancer cell lines, the expression of p16/INK4a, p27/KIP1, cyclin D1, and cyclin E was determined by an enzyme-linked immunosorbent assay (ELISA) of the estrogentreated cells.
After 24, 48, and 72 hours of estrogen treatment, cells were washed with PBS and fixed in 75% ethanol for 10 minutes. This was followed by incubation with acetic acid 0.03% in a phosphate buffer solution for 30 minutes. Nonspecific binding sites were blocked with normal goat serum (DAKO, Glostrup, Denmark), and diluted 1:20 in Tris-buffered saline for 30 minutes at room temperature.
The cells were then reacted with the following antibodies and working dilutions: mouse anti-p16
Mts1 clone G175e405 (BD Pharmingen, Hamburg, Germany; 1:1000), mouse antip27, clone 1B4 (Novocastra; 1:50), rabbit anticyclin E (M-20; Santa Cruz Biotechnology, Heidelberg, Germany), and rabbit anti-cyclin D1 (H-295; Santa Cruz Biotechnology; 1:100) for 60 minutes at 37 C. After washing, cells were then reacted with goat antimouse or goat antirabbit alkaline phosphatase-labeled secondary antibodies (Dako Cytomation California Inc, Carpinteria, CA, USA; 1:500 diluted) for another 60 minutes at 37 C. Finally, the cells were incubated with 7 mM of p-nitrophenyl phosphate (Sigma-Aldrich Corp, St Louis, MO, USA) in a 0.01 M sodium bicarbonate buffer, pH 10.0, for 30 minutes, then read by a Multiscan (Labsystems) at an optical density of 410 nm.
The expression of p16/INK4a, p27/KIP1, cyclin D1, and cyclin E at each condition was calculated as follows:
Statistical analysis
Statistical analysis of the data was performed with Statistica version 5.1 (StatSoft Holdings Inc, Tulsa, OK, USA) and SPSS version 12.0 (SPSS Inc, Chicago, IL, USA). Every experiment was repeated six times. Experimental data were presented as mean AE standard deviation, using the Dunnet test. Statistical analysis was performed by repeated analysis of variance (ANOVA), with a post hoc test for between-group analysis. A p value less than 0.05 was considered statistically significant.
Results
Expression of ERa and ERb
We used MCF7 breast cancer and DU145 prostate cancer cells for positive control of ERa and ERb, as mentioned. 16 There was neither ERa nor ERb mRNA expression in OC-117-VGH. By contrast, both ERa and ERb were identified in OVCAR3 (Fig. 1). 
Inhibition effect of estrogen on cell proliferation of ovarian cells
We first evaluated the survival rate of OC-117-VGH and OVCAR3 ovarian adenocarcinoma cell lines treated with different concentrations of estrogen. The concentrations of estrogen in the culture medium ranged from 0.01 mM to 1.0 mM. The survival of both cancer cells in this study was significantly impaired when using the estrogen treatment. Even at the low concentration of 0.01 mM of estrogen, only 60% of the cancer cells survived (Fig. 2) , independent of the presence or absence of ERa or ERb. In addition, this impaired survival of the ovarian cancer cell line seemed to be estrogen dose-dependent, when the concentration of estrogen was less than 0.1 mM, although this dose-dependent difference seemed to be less significant between 0.01 mM and 1.0 mM. Both cell lines also showed a time-dependent effect of estrogen on cancer cell survival (Fig. 3) , although the time-dependent effect of estrogen on ER-positive OVCAR3 cancer cells seemed to be less significant. The longer the OC-117-VGH Survival rate relative to controlð%Þ ¼ Absorbance of treated wells À mean absorbance of background Absorbance of control wells À mean absorbance of background Â 100%
Percentage relative to controlð%Þ ¼ Absorbance of treated wells À mean absorbance of background Absorbance of control wells À mean absorbance of background Â 100% ovarian cancer cell line was exposed to estrogen, the greater the effect on cancer cell survival (Fig. 3) .
Expression of cyclin D1 and E in estrogen-treated ovarian cancer cell lines
The expression of cyclin D1 and E of both ovarian cancer cells treated with different concentrations (0.01e1.0 uM) of estrogen are shown in Figs. 4 and 5 . Although the expression of cyclin D1 or cyclin E seemed to trend toward an increase when the concentration of estrogen increased from 0.01 mM to 1.0 mM, respectively (Figs. 4 and 5) , and this trend seemed to differ between OC-117-VGH and OVCAR3 cells, the increased cyclin D1 expression was more prominent in the ER-negative OC-117-VGH cells; by contrast, the increased cyclin E expression was more prominent in the ER-positive OVCAR3 cells. However, neither were statistically significant (Figs. 4 and 5, both p > 0.05), suggesting that estrogen might not affect cyclin D1 and E expression when these ovarian cancer cell lines were treated with different concentrations, ranging from 0.01 mM to 1.0 mM of estrogen.
The cyclin D1 and E expression of both ovarian cancer cells treated with durations of estrogen ranging from 24 to 72 hours is shown in Figs. 6 and 7. A pattern similar to the one previously described was noted in this time-dependent study. Although the expression of cyclin D1 and E seemed to trend toward an increase compared to the control and cyclin E was more prominent in the ER-positive OVCAR3 cells than in the ER-negative OC-117-VGH cells, and by contrast, the cyclin D1 was prominent in the ER-negative OC-117-VGH cells, neither reached statistical significance (Figs. 6 and 7, both p > 0.05). These data suggest that estrogen might not affect cyclin D1 and E expression when these ovarian cancer cell lines are treated with estrogen for durations ranging from 24 hours to 72 hours.
Expression of p16/INK4a and p27/KIP1 in estrogentreated ovarian cancer cell lines
The expression of p16/INK4a, and p27/KIP1 of both ovarian cancer cells treated with different concentrations (0.01e1.0 mM) of estrogen are shown in Figs. 8 and 9 . The expression of p16/INK4a showed a significant increase (40%) in the ER-negative OC-117-VGH cells when the concentration of estrogen was increased from 0.01 mM to 1.0 mM (Fig. 8) . However, the p16/INK4a expression of the ER-positive OVCAR3 did not show a change with different concentrations of estrogen treatment. For the expression of p27/KIP1, a similar finding was noted in the ER-negative OC-117-VGH cells, i.e., a progressively increased expression of p27/KIP1 Fig. 2 . Dose effect of estrogen (24 hours) on the survival rate (n ¼ 6). was noted when the concentration of estrogen was increased from 0.01 mM to 1.0 mM (Fig. 9) . The expression of p27/KIP1 was also similar to that of p16/INK4a in the ER-positive OVCAR3 cells (Fig. 9) .
The expression of p16/INK4a and p27/KIP1 of both ovarian cancer cells treated with estrogen ranging from 24 hours to 72 hours is shown in Figs. 10 and 11 . The expression of p16/INK4a was significantly increased (almost 50%) in the ER-negative OC-117-VGH cells when the time exposure to estrogen was increased from 0 hours to 72 hours (Fig. 10) ; however, the expression of p16/INK4a was also increased in the ER-positive OVCAR3 cells, although the increase was not statistically significant (Fig. 10) .
A similar finding was noted in the ER-negative OC-117-VGH cells; i.e., a time-dependent increased expression of p27/KIP1 was seen in the ER-negative OC-117-VGH cells (Fig. 11) ; however, the ER-positive OVCAR3 cells did not show a change of expression of p27/KIP1, even though the time exposure reached 72 hours (Fig. 11) .
These results show that the response of the four cell-cycle regulatory proteins, including cyclin D1, cyclin E, p16/INK4a, and p27/KIP1 in the OC-117-VGH (negative for ERa and ERb) cells or the OVCAR3 (positive for ERa and ERb) cells was different, and although estrogen did inhibit growth in both cell lines, this inhibitory effect might not be always mediated through the classic estrogen-ER pathway.
Discussion
Although the origin of ovarian tumor is still uncertain, epithelial ovarian cancers appear to arise from the ovarian surface epithelium. 34 Repeated ovulation, which requires cyclic destruction and repair of the ruptured ovarian surface epithelium, is supposed to be one of the possible mechanisms contributing to the neoplastic transformation of the ovarian surface epithelium. 35 Therefore, it has been suggested that endocrine and autocrine factors may influence the occurrence of ovarian tumors. 16 The WHI study showed an increased risk of ovarian cancer in women who were long-term users of estrogen and progesterone. 14, 15 However, some articles reported contradictory results, 36e38 which may be due to differences in methodology and the existence of uncontrolled confounding factors. 16 There is no doubt that estrogens might be one of the causative factors of ovarian cancer, 39 because estrogen levels are more than 100-fold greater within the ovarian tissue and much higher in the ovulatory follicle than in circulating levels. Some studies have found a stimulatory effect of estrogen on the growth of normal and malignant ovarian surface epithelium cells. 40 These mitogenic effects are mediated through activation of the interleukin-6/signal transducer and activation of the transcription-3 (STAT-3) signaling pathway, and ovarian cancer cells express high levels of constitutively activated STAT-3, a known transforming cellular molecule. 41 In the previous study, we indicated one of the possible mechanisms to explain estrogen-impaired tumor survival in the OC-117-VGH ovarian cancer cell line. This mechanism was the downregulation of antiapoptotic Bcl-2 and proapoptotic Bax proteins, especially, and more significantly, the declined expression of Bcl-2, which contributed to the net effect of reduced survival of this ER-negative ovarian cancer cell line. 16 The cell cycle progression control should be coordinated by many protein factors, including cyclins, cyclin-dependent kinases (CDKs), and cyclin-dependent kinase inhibitors (CKIs), and this coordination of cell cycle control is related to tumor cell proliferation, differentiation, and apoptosis. 42 In this study, we evaluated the changes in cell-cycle inhibitory proteinsdp16/INK4a and p27/KIP1, and cell-cycle stimulatory proteinsdcyclin D1 and cyclin E, in ovarian cancer cell lines to explore other possible mechanisms contributing to the decreased survival of ovarian cancer cell lines after estrogen treatment. Cyclin D was reported to play a dominant role in regulating cell cycle progression in ovarian cancer, and degradation of cyclin D1 is sufficient to induce G1 cell cycle arrest. 43 Cyclin E has been shown to compensate for knockout of cyclin D during fetal development, 44 and under normal conditions, expression of cyclin E is controlled by cyclin D through activation of CDK4/6 hypophosphorylation of pRb. 45, 46 However, in this study, we did not find a change in the expression of cyclins D1 and E in either cell line, suggesting that the suppression of cell growth in the ovarian cancer cell linesdeither ER-positive OVCAR3 cells or ERnegative OC-117-VGH cellsdafter estrogen treatment might not involve these two types of proteins.
By contrast, inhibitory proteins in the cell cycle, including p16/INK4a and p27/KIP1, seemed to be dramatically altered in this study. In addition, ER-positive and ER-negative ovarian cancer cell lines showed a different response after estrogen treatment. Estrogen exerted its growth suppression effects on OC-117-VGH cells in this study by acting on the G1/S cell checkpoints, because estrogen upregulated p27/KIP1 expression in the OC-117-VGH cells. Increased p27/KIP1 expression was reported to decrease CDK4/6 activity and lead to a decrease in the levels of Skp2 and cyclin E, and cyclin A/ CDK2 activity and blocks the entry of cells in the G1 to S phase. 45 However, this phenomenon of an increased p27/KIP1 expression in the OC-117-VGH cell line was not found in the ER-positive ovarian cancer cell lines, because estrogen-treated OVCAR3 cells in serial concentrations or serial time exposures did not show altered p27/KIP1 expression.
Our observation when we studied p16/INK4a expression in ovarian cancer cell lines treated with estrogen was similar to that of p27/KIP1 expression. The ER-negative OC-117-VGH cell line showed a significant increase in p16/INK4a expression after estrogen treatment, and this effect was also shown as dose-and time-dependent. Inactivation of p16/INK4a results in loss of inhibition of retinoblastoma phosphorylation, facilitating a loss of control of cell cycle arrest. 45 For example, MDA-MB-453, one of the breast cancer cell lines, and one that is androgen-positive and "triple-negative" with respect to ERa, progesterone receptor and Her-2/neu protein expression, and characterized as having a loss of the p16/INK4a gene, as evidenced by the lack of p16/INK4a protein expression in Western blot analysis and immunocytochemistry assays, showed a rapid cell growth pattern and possessed highly invasive and migratory behavior. 46 However, this phenomenon of an increased p16/INK4a expression in the ER-negative OC-117-VGH cell line was not found in the ER-positive ovarian cancer cell line, because estrogen-treated OVCAR3 cells in serial concentrations or serial time exposures did not show altered p16/INK4a expression, suggesting that the possible pathways of growth suppression after estrogen treatment of ER-positive and ER-negative ovarian cancer cell lines might be different, respectively.
Regarding study limitations, as the OVCAR3 cell line is positive for ERs, the effects of estrogen on cell survival may be mediated through the classic estrogen/ER pathway, which means that estrogen passes into the cytoplasm and binds ER and enters into the nucleus with binding DNA and activates the estrogen response elements. 27, 28 However, we did not examine the classic estrogen/ER pathway to prove our observation that estrogen decreased survival and/or growth in the OVCAR3 cells. We also failed to detect the typical morphologic characteristics of apoptosis, such as compaction and margination of chromosomes, nuclear fragments, and the formation of apoptotic bodies in our previous study 16 and this study (data not shown), although growth suppression was prominent herein. Therefore, it was difficult to claim that the decreased survival and/or growth may have been due to factors other than cytotoxicity, although similar studies using the different ER-positive cell lineseSKOV-3 confirmed these effects might not be mediated by cytotoxicity. 16, 40 The decreased human cancer cell population in vitro, as observed in this study, reflects a change in the balance of the cell cycle and could involve arrested cell proliferation, enhanced cell death, or both, at least in the ER-negative OC-117-VGH cell line; however, we did not identify which one was predominant.
In conclusion, the current study indicated that estrogen did impair tumor survival in the ER-negative OC-117-VGH and ER-positive OVCAR3 ovarian cancer cell lines. Although estrogen-induced upregulation of p16/INK4a and p27/KIP1 proteins was found only in the ER-negative OC-117-VGH cells, and not in the ER-positive OVCAR3 cells, our results supposed the possibility of relationship between estrogen and ovarian cancer, regardless of the presence or absence of ER expression.
